Roxatidine
Structural formula | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||
Non-proprietary name | Roxatidine | ||||||||||||
other names |
|
||||||||||||
Molecular formula | C 17 H 26 N 2 O 3 | ||||||||||||
External identifiers / databases | |||||||||||||
|
|||||||||||||
Drug information | |||||||||||||
ATC code | |||||||||||||
Drug class | |||||||||||||
Mechanism of action | |||||||||||||
properties | |||||||||||||
Molar mass | 306.4 g · mol -1 | ||||||||||||
safety instructions | |||||||||||||
|
|||||||||||||
Toxicological data | |||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Roxatidine ( Roxatidine Acetate) (trade name: Roxit) is a drug from the group of H 2 antagonists for the treatment of gastric and duodenal ulcers .
effect
Roxatidine acts as a competitive histamine antagonist on the parietal cells of the stomach and thus inhibits acid secretion. As an acetate, it has a four times stronger antisecretory effect than cimetidine .
Pharmacokinetics
Roxatidine is taken in the form of roxatidine acetate, a prodrug that is metabolized by the body to the actual active ingredient. Roxatidine acetate is quickly absorbed after oral intake and deacylated to roxatidine in the body. The maximum plasma level is reached after 2–3 hours. Within 24 hours, more than 90% of the administered acetate appears as roxatidine in the urine. The main metabolite of acetate is 55% roxatidine, there are at least 9 others.
dosage
The usual daily dose is 150 mg, with an application period of 4 to 8 weeks.
Contraindications
- Anuria
- Children under 14 years
- Liver dysfunction (no thermal experience)
A small amount of roxatidine passes into the central nervous system and into breast milk .
unwanted effects
Allergic effects such as itching and rash can occur rarely, as well as headache (1%), sleep disorders, restlessness, fatigue, tachycardia (rarely), diarrhea (1%), constipation (0.5%).
There is no evidence of a mutagenic , teratogenic or carcinogenic effect.
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ a b c d e f g F. von Bruchhausen et al .: Hager's handbook of pharmaceutical practice . Vol. 9, fabrics P – Z, 1994, p. 535 ff. ( Limited preview in the Google book search).